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in HIV-infected patients requiring acute
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Abstract
Background: We previously reported that one-third of HIV-positive adults requiring medical admission to a South
African district hospital had laboratory-confirmed tuberculosis (TB) and that almost two-thirds of cases could be rapidly
diagnosed using Xpert MTB/RIF-testing of concentrated urine samples obtained on the first day of admission.
Implementation of urine-based, routine, point-of-care TB screening is an attractive intervention that might be facilitated
by use of a simple, low-cost diagnostic tool, such as the Determine TB-LAM lateral-flow rapid test for HIV-associated TB.
Methods: Sputum, urine and blood samples were systematically obtained from unselected HIV-positive adults within
24 hours of admission to a South African township hospital. Additional clinical samples were obtained during
hospitalization as clinically indicated. TB was defined by the detection of Mycobacterium tuberculosis in any sample using
Xpert MTB/RIF or liquid culture. The diagnostic yield, accuracy and prognostic value of urine-lipoarabinomannan (LAM)
testing were determined, but urine-LAM results did not inform treatment decisions.
Results: Consecutive HIV-positive adult acute medical admissions not already receiving TB treatment (n = 427) were
enrolled regardless of clinical presentation or symptoms. TB was diagnosed in 139 patients (TB prevalence 32.6%; median
CD4 count 80 cells/μL). In the first 24 hours of admission, sputum (spot and/or induced) samples were obtained from
37.0% of patients and urine samples from 99.5% of patients (P < 0.001). The diagnostic yields from these
specimens were 19.4% (n = 27/139) for sputum-microscopy, 26.6% (n = 37/139) for sputum-Xpert, 38.1% (n = 53/139)
for urine-LAM and 52.5% (n = 73/139) for sputum-Xpert/urine-LAM combined (P < 0.01). Corresponding yields among
patients with CD4 counts <100 cells/μL were 18.9%, 24.3%, 55.4% and 63.5%, respectively (P < 0.01). The diagnostic
yield of urine-LAM was unrelated to respiratory symptoms, and LAM assay specificity (using a grade-2 cut-off) was 98.
9% (274/277; 95% confidence interval [CI] 96.9–99.8). Among TB cases, positive urine-LAM status was strongly
associated with mortality at 90 days (adjusted hazard ratio 4.20; 95% CI 1.50–11.75).
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Conclusions: Routine testing for TB in newly admitted HIV-positive adults using Determine TB-LAM to test urine
provides major incremental diagnostic yield with very high specificity when used in combination with sputum testing
and has important utility among those without respiratory TB symptoms and/or unable to produce sputum. The assay
also rapidly identifies individuals with a poor prognosis.
Keywords: Tuberculosis, HIV, Diagnosis, Urine, Xpert, Lipoarabinomannan, LAM, Africa, Screening, Hospital,
Determine TB-LAM
Background
Tuberculosis (TB) is the leading cause of HIV/AIDS-related
mortality globally, accounting for an estimated 0.4 million
HIV-related deaths worldwide in 2015 [1, 2]. A large major-
ity of these deaths occur in sub-Saharan Africa. Post-
mortem studies conducted in African hospitals over the
past 20 years have revealed that between 32% and 67%
(pooled summary prevalence estimate 39.7%; 95% confi-
dence interval [CI] 32.4–47.0) of HIV-positive adult pa-
tients had evidence of TB disease at autopsy [3–5] and that
this was the primary cause of death in over 90% of these
cases [6]. Disease was frequently disseminated and approxi-
mately half of these cases remained undetected prior to
death [6]. These findings suggest the need for new
approaches to routine diagnostic screening for TB in HIV-
infected patients newly admitted to hospital in resource-
limited settings.
Using an intensive clinical sampling approach, we have
previously demonstrated that one in three unselected HIV-
infected acute medical adult admissions to a South African
township district hospital had TB that could be diagnosed
microbiologically [7]. Presentation was so non-specific that
neither symptom screening nor risk profiling were suffi-
cient to reliably identify a low-risk group that did not war-
rant further laboratory investigation for TB. We therefore
concluded that to maximize TB case ascertainment, all
HIV-infected patients newly admitted to hospital in settings
with high TB burden should be investigated for TB using
microbiological tests regardless of their clinical presenta-
tion. Unfortunately, laboratory capacity is often severely
limited in resource-limited settings. Moreover, it is fre-
quently challenging to obtain sputum samples from sick
medical inpatients, even from those suspected of having
pulmonary TB [8, 9]. Conversely, urine can be readily col-
lected from the vast majority of patients, and we [7] and
others [10] have previously demonstrated that Xpert MTB/
RIF testing of urine samples concentrated by centrifugation
assay provides a substantial diagnostic yield of TB in this
patient population. However, implementing such a strategy
in resource-limited settings can be hindered by the cost,
and the need for laboratory infrastructure with a reliable
electricity supply to allow urine centrifugation and Xpert
MTB/RIF testing. In the present study, we therefore ex-
plored the utility of the Determine TB-LAM© (Alere Inc.,
Waltham, MA, USA) lateral-flow urine assay—a technically
much simpler, instrumentation-free, low-cost, point-of-care
diagnostic tool [11]. We reasoned that this could be used to
test urine samples within the emergency admission unit or
ward environment without the need for laboratory infra-
structure, and might therefore be more feasibly imple-
mented at more remote health facilities in resource-limited
settings. In this study, we report on the diagnostic accuracy
of the Determine TB-LAM test and its incremental diag-
nostic yield when used in combination with sputum-based
diagnosis. We also report on the strong association between
urine-lipoarabinomannan (LAM) status and mortality dur-
ing 90 days of follow-up.
Methods
Setting and patients
This study forms part of a larger study of rapid urine-based
approaches to diagnosis of HIV-associated TB that has pre-
viously been reported [7]. The prospective, observational
cohort reported herein was enrolled at G.F. Jooste Hospital
in Cape Town, South Africa. This 200-bed adult district
hospital serves township communities in which there is a
high seroprevalence of HIV and incidence of TB. This study
was approved by the Human Research Ethics Committees
of the University of Cape Town and the London School of
Hygiene & Tropical Medicine. Patients provided written in-
formed consent in their first language. The study is re-
ported according to STARD initiative guidelines for
reporting studies of diagnostic accuracy [12].
Adult patients aged ≥18 years were recruited on
4 days of the week from medical wards. On recruitment
days, the study nurse coordinator ascertained from the
ward register all medical admissions in the previous 24-
hour period and recorded these in the study register.
All patients who either previously tested negative or
who had undocumented HIV status were offered HIV
testing using two approved rapid tests. All patients who
had a current TB diagnosis and/or were receiving treat-
ment for TB at the time of hospital admission were ex-
cluded from the present study. Otherwise, all other
adult patients with documented positive HIV status
were eligible for the study and were invited to partici-
pate regardless of presenting symptoms or reason for
hospital admission.
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Procedures and samples
Demographic and clinical details (including the World
Health Organization [WHO] four-symptom screen for
HIV-associated TB [13]) were recorded. The research
team systematically investigated patients by obtaining
sputum, urine and blood specimens for TB investiga-
tions between 9.00 a.m. on the day of enrolment and
9.00 a.m. the following day. Numerous additional sam-
ples (including both sputum and non-respiratory sam-
ples) for mycobacteriology were obtained by the routine
medical team according to clinical indication throughout
the admission period (Additional file 1: Table S1).
In the initial 24-hour period of hospital admission, two
sputum samples were requested from each patient with
careful instruction and supervision by the study nurse co-
ordinator (an experienced respiratory nurse) as previously
described [7]. A spot specimen was obtained first,
followed by a second sample, which was induced using
nebulized 3% hypertonic saline. When necessary, both
specimens were induced. Alternatively, for those either
too unwell to leave the ward to attend the sputum induc-
tion facility or too unwell for the sputum induction pro-
cedure, two spot specimens were requested. Urine
samples were systematically collected in single-use
disposable bedpans (Litha Healthcare Group, Johannes-
burg, South Africa). Fresh aliquots (2.0 mL) were sent for
Xpert testing and the remaining urine volume (30–40 mL)
was stored at –20 °C. Venous blood (5.0 mL) was inocu-
lated into BACTEC™ Myco F/Lytic culture vials (Becton
Dickinson, Franklin Lakes, NJ, USA).
Laboratory procedures
Specimens were processed using standardized protocols
in centralized accredited laboratories of the South African
National Health Laboratory Service as described previ-
ously [14, 15]. Decontaminated, centrifuged deposits of
sputum samples were re-suspended in phosphate buffer.
Smears stained with auramine O stain were examined
with fluorescence microscopy. Equal volumes were tested
using Xpert and culture in mycobacterial growth indicator
tubes (MGIT; Becton Dickinson, Sparks, MD, USA),
which were incubated for up to 6 weeks. Culture isolates
were identified as M. tuberculosis complex with the
MTBDRplus assay (Hain Lifesciences, Nehren, Germany).
Non-respiratory samples were also tested using MGIT li-
quid culture, with the exception of venous blood, which
was tested using Myco F/Lytic culture.
Urine was tested using Xpert MTB/RIF in two differ-
ent ways as described previously [7]. Fresh urine samples
(2.0 ml) were centrifuged and the pellet re-suspended in
0.75 mL of phosphate buffer before testing using the
Xpert MTB/RIF assay [7]. Each stored urine sample of
between 30 and 40 mL was thawed and centrifuged at
3000 × g for 15 min. Following removal of the supernatant,
the pellet was re-suspended in the residual urine volume
and 0.75 mL was tested using Xpert. This second sample
derived from centrifugation of a large urine volume
was referred to as the ‘concentrated’ urine sample and
these samples were batch processed on a weekly basis
due to study-related logistical considerations and la-
boratory workflow.
The same frozen urine samples (unconcentrated and un-
processed) were also retrospectively tested for the presence
of LAM using the Determine TB-LAM test (Alere Inc.) fol-
lowing the manufacturer’s instructions. Samples were
thawed to ambient temperature and for each sample, 60 μL
of unprocessed urine was applied to the sample pad at the
bottom of the test strip. After 25 min, test strips were inde-
pendently read by two investigators (SDL and MV) blinded
to patient status and all other test results. Having checked
for the presence of the positive control band on each strip,
test results were scored as grade 1, 2, 3, 4 or 5 when com-
pared to the reference card as described elsewhere [13]. For
example, for the test result to be scored as grade 2, the test
band had to be at least as intense as the corresponding
grade 2 band on the reference card but not as intense as
the grade 3 reference band. Any discrepancies in scoring
were reviewed by both readers and the result resolved and
agreed within 35 min of initial urine application. After reso-
lution of results, the grade scores were categorized as being
‘positive’ (grade 2 or higher) or ‘negative’ (no test band at
least as intense as grade 2).
Results of all microbiological tests were returned to
the clinical team to inform treatment decisions with the
exception of the results of the Determine TB-LAM
assay, which was not endorsed for clinical use in South
Africa or by the WHO at the time of the study.
Clinical outcomes
Patient and ward records as well as district, regional and
national electronic data systems were used to ascertain
deaths during the first 90 days following enrolment as
fully described elsewhere [16]. Patients with an uncon-
firmed vital status at 90 days (<5%) were considered to
be lost to follow-up and data were censored on the last
date of contact with the health system.
Data analysis
Diagnostic yield of Determine TB-LAM and relationship with
patient symptoms and other characteristics
The diagnostic reference standard for a confirmed new
TB diagnosis was the detection of M. tuberculosis from
at least one clinical sample of any type using MGIT cul-
ture and/or Xpert MTB/RIF. The total number of con-
firmed cases (n = 139) was used as the denominator to
calculate the comparative diagnostic yield obtained from
different sample types and different assays, including
Determine TB-LAM. The yield of TB diagnoses from
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Determine TB-LAM testing of urine samples obtained
during the initial 24 hours was compared with the yield
from sputum samples collected in the same period. We
included Xpert results in our diagnostic reference stand-
ard. While we calculated the yield of diagnoses made by
Xpert in different specimen types compared with other
methods, this does not represent a measure of diagnostic
sensitivity (calculation of sensitivity was not performed).
Diagnostic yield in our study reflected both the perform-
ance of the diagnostic test and the ability to obtain sam-
ples for that test in a real-world clinical setting. The
associations between the yield of Determine TB-LAM
and patient symptoms and other patient characteristics
were explored and multivariable logistic regression was
used to identify factors independently associated with
positive urine-LAM status among patients with con-
firmed TB. One or more positive reference standard
tests on a non-respiratory sample was taken as evidence
of extrapulmonary TB (EPTB).
Diagnostic accuracy of Determine TB-LAM
For the purposes of assessing the diagnostic accuracy (sen-
sitivity and specificity) of Determine TB-LAM, we identified
a cohort of patients for whom sufficient microbiological
data and the results of Determine TB-LAM urine testing
were available. For inclusion in this analysis, patients were
required to have the results of reference standard tests (li-
quid culture and/or Xpert MTB/RIF) from two or more
samples obtained from two or more different anatomic
sites, such as blood, sputum, urine or other non-respiratory
samples. The rationale for this was to reduce the risk of pa-
tients with disseminated TB having false-negative reference
standard tests and being inappropriately designated as ‘TB-
free’. By doing so, we enhanced the methodological rigour
with which the specificity of Determine TB-LAM was
assessed [17]. From this cohort, those testing positive for
M. tuberculosis were used as the denominator to calculate
the sensitivity of Determine TB-LAM (n = 136). In contrast,
patients whose clinical samples all tested negative forM. tu-
berculosis were defined as ‘TB-free’ and were used as the
denominator to calculate the specificity of Determine TB-
LAM (n = 277).
Patient characterization
Patients were characterized using simple descriptive statis-
tics. Anaemia severity was defined using WHO criteria:
no anaemia (haemoglobin concentration ≥13.0 g/dL for
males, ≥12.0 g/dL for females), mild anaemia (11.0–
12.9 g/dL for males, 11.0–11.9 g/dL for females), moder-
ate anaemia (8.0–10.9 g/dL for males and females) or se-
vere anaemia (<8.0 g/dL for males and females) [18]. TB
prevalence with 95% exact confidence intervals (95% CI)
was calculated. Medians were compared using either Wil-
coxon rank-sum tests or Kruskal–Wallis tests as
appropriate and means were compared using unpaired t
tests. Chi-squared, Fisher’s exact and McNemar’s tests
were used as appropriate to compare proportions.
Kaplan–Meier plots were used to examine mortality risk
among confirmed TB cases stratified by urine-LAM status
and a Cox proportional hazards model was used to deter-
mine factors associated with mortality. Person-time was
accrued from the date of study enrolment until death, loss
to follow-up or censorship 90 days after study entry. All
variables in the univariable model meeting a cut-off of P ≤
0.1 were included in the multivariable model. Statistical
tests were two-sided at α = 0.05.
Results
Patients enrolled and their characteristics
Between 6 June 2012 and 4 October 2013, the HIV sta-
tus of 1013 of 1018 (99.5%) unselected new admissions
to the adult medical wards was ascertained (Fig. 1). Of
the 609 patients with a documented positive HIV test,
585 (96.1%) were willing to participate in the study.
Those already receiving treatment for an existing diag-
nosis of TB at the time of admission (n = 158, 27.0%)
were excluded, leaving 427 eligible patients who formed
the study cohort (Fig. 1).
Patients were typically young adults; a majority knew
their positive HIV status before admission and more than
half of all patients had previously started antiretroviral
therapy (ART) (Table 1). Immunodeficiency was typically
advanced and overall median CD4 cell counts were lower
among those who were ART-naive compared to those cur-
rently receiving ART (115 cells/μL versus 212 cells/μL; P
< 0.001). Nearly half of all patients had previously received
treatment for TB and two-thirds had moderate or severe
anaemia (Table 1).
Samples tested and laboratory-confirmed TB diagnoses
made
During hospital admission, clinical samples for mycobac-
teriology were obtained from all 427 eligible study partici-
pants. The total of 1745 samples (mean 4.1 samples per
patient) were derived from a median of three anatomic lo-
cations (Additional file 1: Table S1). These yielded 2391
reference standard test results (mycobacterial liquid cul-
ture and Xpert MTB/RIF). Results were missing for 4.3%
of sputum cultures (n = 12), which were contaminated,
and 4.3% of sputum Xpert tests (n = 12) and 3.1% of urine
Xpert tests (n = 26), which had indeterminate results.
However, all urine samples yielded interpretable LAM re-
sults (n = 418). TB was diagnosed in 139 patients with a
mean of 3.2 positive samples per case diagnosed. Thus,
the overall TB prevalence was 32.6% (95% CI 28.1–37.2).
The mean number of tests done was similar for patients
in whom TB was or was not diagnosed (5.8 tests versus
5.5 tests, respectively; P = 0.154, indicating a comparable
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intensity of investigation). The characteristics of those
with and without TB are summarized in Table 1. Com-
pared with those who were TB-free, those with a new TB
diagnosis had lower CD4 counts and lower haemoglobin
levels. The vast majority of patients had a positive WHO
symptom screen regardless of TB status, but only one-
third of patients (with or without TB) reported sputum
production prior to admission.
Diagnostic accuracy of Determine TB-LAM urine testing
Having carefully defined which patients in the cohort had
TB and which were TB-free, the diagnostic accuracy of
urine-LAM was next assessed using data from the subset of
413 patients (96.7%) for whom reference standard test re-
sults on samples obtained from at least two anatomic sites
plus urine-LAM results were available and complete (Fig. 1).
In this subset of patients, TB was diagnosed in 136
patients and this was used as the denominator to cal-
culate the sensitivity of Determine TB-LAM. Culture
and Xpert tests were negative on all samples obtained
from the remaining patients (n = 277), who were
therefore designated as ‘TB-free’ and used to assess
the specificity of Determine TB-LAM. Among these
277 patients, the mean number of negative reference
standard tests per patient was 5.5.
Using the grade 2 reference band as the cut-off to
designate urine-LAM results as ‘positive’ or ‘negative’
[13], the Determine TB-LAM results of the two inde-
pendent readers of the lateral-flow tests were con-
cordant in 407 of 413 tests, giving a proportionate
agreement of 98.5% (95% CI 96.7–99.5) and a kappa
statistic of 0.937 (95% CI 0.887–0.987). Following re-
view of the discordant results from the remaining six
tests, the two readers readily agreed upon a consen-
sus result for each. Thus, TB-LAM results in agree-
ment were available for all 413 patients.
Urine-LAM was positive in 53 of 136 TB cases, giving
an overall sensitivity of 39.0% (95% CI 30.7–47.7).
Urine-LAM was negative in 274 of the 277 patients
who were TB-free, giving a specificity of 98.9% (95% CI
96.9–99.8). Two of three patients with apparent false-
positive urine-LAM results had clinico-radiological
diagnoses of TB made by the routine medical team, al-
though diagnoses were never confirmed microbiologic-
ally. Of note, neither had a full set of investigations
available, with sputum and blood culture results miss-
ing. One patient had a 3-week history of weakness,
diarrhoea and constitutional symptoms, was pancyto-
paenic (grade 2 LAM-positive), and subsequently died
without any diagnosis being made. The other patient
had a 3-month history of abdominal pain and weight
loss, and an abdominal ultrasound demonstrated
splenomegaly and splenic micro-abscesses with para-
aortic and mesenteric lymphadenopathy suggestive of
abdominal TB (grade 5 LAM-positive). Thus, had a
composite reference standard for TB diagnosis (all
microbiological and clinico-radiological diagnoses) been
used in a post hoc analysis, the specificity would have
been 279 out of 280 TB-free patients (99.6%; 95% CI
98.0–100). Using a grade 1 reference band cut-off
Fig. 1 Flow diagram showing the study population and the numbers of patients included. HIV human immunodeficiency virus, TB tuberculosis
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resulted in modest improvement in sensitivity with a
small decrease in specificity (Additional file 2: Table
S2). Both grade 1 and 2 reference band cut-offs had im-
proved sensitivity when restricted to those with CD4
counts <100 cells/μL (56.9% and 68.1% using grade 2
and grade 1 cut-offs, respectively).
Comparative diagnostic yield of urine and sputum
samples obtained in the first 24 hours
Given the very high specificity of urine-LAM, a positive
Determine TB-LAM result was indicative of TB (posi-
tive predictive value [95% CI 85.1-98.9]). We therefore
next compared the diagnostic yield of urine-LAM,
Table 1 Characteristics of all patients stratified according to tuberculosis status
All patients
(n = 427)
Patients with a TB diagnosis
(n = 139)
Patients without a TB diagnosis
(n = 288)
P value
Age (years), median (IQR) 36.1 (28.9–42.4) 33.8 (27.2–39.7) 37.1 (30.0–44.0) 0.008
Female 259 (60.7) 90 (64.8) 169 (58.7) 0.229
New HIV diagnosis on admission 82 (19.2) 34 (24.5) 48 (16.7) 0.055
TB characteristics
History of previous TB* 196 (46.1) 50 (36.2) 146 (50.9) 0.005
RIF resistance 4 (0.9) 4 (2.9) 0 0.004
ART status
ART-naive 177 (41.5) 71 (51.1) 106 (36.8) 0.019
ART interrupted 71 (16.6) 19 (13.7) 52 (18.1)
Current ART use 179 (41.9) 49 (35.3) 130 (45.1)
Treatment duration if currently on ART (years), median (IQR)a 1.6 (0.6–3.6) 1.3 (0.2–2.9) 1.7 (0.6–3.7) 0.157
CD4 counts (cells/μL)*
Median (IQR) 149 (55–312) 80 (33–182) 191 (73–392) <0.001
<50 94 (22.2) 53 (38.4) 41 (14.3)
50–99 66 (15.6) 21 (15.2) 45 (15.7)
100–149 54 (12.7) 19 (13.8) 35 (12.2)
150–199 42 (9.9) 16 (11.6) 26 (9.1)
≥200 169 (39.9) 29 (21.0) 140 (49.0)
HIV viral load (log copies/mL)b
Median (IQR) 4.4 (1.6–5.5) 5.1 (3.3–5.8) 4.0 (1.6–5.4) <0.001
Virally suppressed (<400 copies/mL) 131 (31.6) 25 (19.8) 106 (36.8) 0.001
Haemoglobin levels*
Median (IQR) 9.6 (7.7–11.6) 8.4 (6.8–10.2) 10.2 (8.2–12.2) <0.001
No/mild anaemia 144 (34.2) 28 (20.1) 116 (41.1)
Moderate/severe anaemia 277 (65.8) 111 (79.9) 166 (58.9)
C-reactive protein (mg/L)c
Median (IQR) 73 (17–153) 112 (70–182) 54 (12–135) <0.001
>50 246 (61.2) 108 (82.4) 138 (50.9) <0.001
Symptoms
Cough ≥2 weeks* 34 (8.0) 18 (13.0) 16 (5.6) 0.008
Sputum production* 161 (38.3) 51 (37.5) 110 (38.7) 0.808
Current cough* 201 (47.4) 84 (60.9) 117 (40.9) <0.001
Current fever* 63 (14.9) 24 (17.5) 39 (13.6) 0.294
Current night sweats* 174 (41.0) 73 (52.9) 101 (35.3) 0.001
Current reported weight loss* 189 (44.5) 76 (55.1) 113 (39.4) 0.002
Positive WHO symptoms screen* 389 (91.5) 134 (97.1) 255 (88.9) 0.005
Data are presented as n (%), unless otherwise stated. *Between 2 and 7 values missing, alimited to among 179 patients currently receiving ART, b13 results
missing, c20 results missing.
Abbreviations: ART antiretroviral therapy, IQR interquartile range, RIF rifampicin, TB tuberculosis, WHO World Health Organization
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sputum-Xpert and sputum microscopy from samples
obtained in the first 24 hours of admission from all 427
included patients.
The potential yield of sputum-based diagnoses was
substantially limited by the high proportion of patients
who were unable to produce a sputum sample. In the
first 24 hours of admission only 158 of 427 (37.0%) pa-
tients were able to produce at least one sputum sample
(spot and/or induced samples) despite assistance from
an experienced respiratory nurse. Of these sputum sam-
ples, 36 (23.1%) were only obtained following sputum in-
duction. The remaining patients who did not produce
sputum were typically too sick or uncooperative to toler-
ate sputum induction or to be taken to the sputum in-
duction room at the hospital, or it was attempted but
was simply unsuccessful. In marked contrast, urine sam-
ples were readily obtained from 425 of 427 (99.5%) pa-
tients, although seven samples were misplaced in transit
to the laboratory, leaving 418 urine samples available for
testing (Fig. 1).
Sputum samples were eventually produced by a total
of 245 patients (57.4%) at some point during their hos-
pital admission. Of the 161 patients who self-reported
sputum production prior to admission, 143 (88.8%) were
able to produce a sputum sample for testing. Addition-
ally, of the 201 patients reporting current cough at
admission, 159 (79.1%) produced a sputum sample.
Figure 2a shows the comparative diagnostic yield of
urine-LAM and sputum-based testing with microscopy
and with Xpert MTB/RIF from samples taken in the first
24 hours. The diagnostic yields obtained from sputum
microscopy, sputum-Xpert and urine-LAM were 19.4%
(n = 27/139), 26.6% (n = 37/139) and 38.1% (n = 53/139),
respectively (comparison of the proportionate diagnostic
yield from sputum microscopy with the yield from
sputum-Xpert and urine-LAM: McNemar’s P < 0.01 for
each comparison).
The incremental diagnostic yield of Determine TB-
LAM used in combination with sputum testing is
shown in Fig. 2a. The addition of urine-LAM testing to
sputum microscopy increased the overall diagnostic
yield from 19.4% to 46.8% (n = 65/139: a 2.4-fold in-
crease; P < 0.001) of all TB cases. The addition of urine-
LAM testing to sputum-Xpert increased the diagnostic
yield from 26.6% to 52.5% (n = 73/139: a 2.0-fold in-
crease; P < 0.001).
Sub-analysis of patients with CD4 cell counts <100 cells/μL
Figure 2b shows the diagnostic yields obtained from spu-
tum microscopy, sputum-Xpert and urine-LAM among
those patients with CD4 cell counts <100 cells/μL (n =
74) for specimens obtained in the first 24 hours of ad-
mission. The diagnostic yield from sputum microscopy,
sputum-Xpert and urine-LAM were 18.9% (n = 14/74),
Table 2 Diagnostic yield of tuberculosis cases from different sample types and the proportion of each diagnosed by Determine TB-LAM
Proportion diagnosed by Determine
TB-LAM (true positives)
Samples from which TB diagnoses were made Number of TB diagnoses Diagnostic yield, %
(95% CI)
Number Proportion, %
(95% CI)
All clinical samples and tests 139 100 53 38.1 (30.0–46.7)
Study samples collected during the first 24 h of admission
Urine
Urine Xpert (unconcentrated) 59 42.4 (34.1–51.1) 37 62.7 (49.1–75.0)
Urine Xpert (concentrated) 82 59.0 (50.3–67.3) 43 52.4 (41.1–63.6)
Sputum
Smear microscopy 27 19.4 (13.2–27.0) 15 55.6 (35.3–74.5)
Xpert (1st sample only) 37 26.6 (19.5–34.8) 17 45.9 (29.5–63.1)
Xpert (either sample) 39 28.1 (20.8–36.3) 17 43.6 (27.8–60.4)
All study samples collected during any point during admission
All EPTB cases* 113 81.3 (73.8–87.4) 51 45.1 (35.8–54.8)
Blood 41 29.5 (22.1–37.8) 27 65.9 (49.4–79.9)
Pleural fluid 13 9.4 (5.1–15.5) 4 30.8 (9.0–61.4)
Urinea 92 66.2 (57.9–74.0) 46 50.0 (39.4–60.6)
Cerebrospinal fluid 8 5.8 (2.5–11.0) 1 12.5 (0.3–52.7)
Lymph node fine needle aspirate 6 4.3 (1.6–9.2) 4 66.7 (22.3–95.7)
*All patients who had evidence of extrapulmonary involvement, i.e. ≥1 non-respiratory sample of any type that tested positive by culture and/or Xpert (regardless
of other results on respiratory samples); aculture and/or Xpert testing.
Abbreviations: CI confidence interval, EPTB extrapulmonary tuberculosis, TB tuberculosis
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24.3% (n = 18/74) and 55.4% (n = 41/74), respectively
(comparison of the proportionate diagnostic yield from
sputum microscopy with the yield from sputum-Xpert
and urine-LAM: McNemar’s P = 0.13 and P < 0.001 for
each comparison, respectively). The addition of urine-
LAM testing to sputum microscopy increased the diag-
nostic yield from 18.9% to 60.8% (n = 45/74: a 3.2-fold
increase; P < 0.001). The addition of urine-LAM testing
Table 3 Characteristics of patients with tuberculosis stratified according to Determine TB-LAM assay result
Among TB patients by LAM status (n = 139)
LAM-positive
(n = 53)
LAM-negative
(n = 83)
No LAM result
(n = 3)
P value*
Age (years), median (IQR) 33.4 (25.9–40.6) 34.2 (28.2–38.7) 25.3 (25.1–32.4) 0.582
Female 30 (56.6) 57 (68.7) 3 (100) 0.153
New HIV diagnosis on admission 19 (35.9) 14 (16.9) 1 (33.3) 0.012
History of previous TBa 17 (32.1) 31 (37.8) 2 (66.7) 0.497
ART status
ART-naive 28 (52.8) 42 (50.6) 1 (33.3) 0.058
ART interrupted 11 (20.8) 7 (8.4) 1 (33.3)
Current ART use 14 (26.4) 34 (41.0) 1 (33.3)
If currently on ART, treatment duration (years), median (IQR)* 0.1 (0–2.5) 1.5 (0.6–4.1) 0.8 (0.8–0.8) 0.055
CD4 counts (cells/uL)a
Median (IQR) cells/μL 42 (23–91) 140 (47–247) 74 (22–546) <0.001
<50 30 (56.6) 22 (26.8) 1 (33.3) <0.001
50-99 11 (20.8) 9 (11.0) 1 (33.3)
100-149 7 (13.2) 12 (14.6) 0
150-199 4 (7.6) 12 (14.6) 0
≥200 1 (1.9) 27 (32.9) 1 (33.3)
HIV viral load (log copies/mL)b
Median (IQR) 5.4 (4.3–6.0) 4.7 (2.5–5.5) 4.5 (3.2–5.9) 0.005
Virally suppressed (<400 copies/mL) 4 (8.0) 21 (26.6) 0 0.011
Anaemia category
Median (IQR) 7.6 (6.5–8.6) 9.0 (7.4–11.1) 7.1 (6.9–11.8) <0.001
No/mild anaemia 3 (5.7) 24 (28.9) 1 (33.3) 0.001
Moderate/severe anaemia 50 (94.3) 59 (71.1) 2 (66.7)
C-reactive protein (mg/L)b
Median, (IQR) 168 (107–204) 95 (44–142) 100 (87–134) <0.001
<50 0 23 (29.5) 0 <0.001
≥50 50 (100) 55 (70.5) 3 (100)
Symptoms
Cough ≥2 weeksa 8 (13.2) 11 (13.4) 0 0.972
Sputum productiona 22 (41.5) 27 (33.8) 2 (66.7) 0.364
Current cougha 31 (58.5) 22 (62.2) 2 (66.7) 0.667
Current fevera 22 (41.5) 27 (33.8) 2 (66.7) 0.436
Current night sweats 11 (21.2) 13 (15.9) 0 0.965
Current reported weight lossa 30 (56.6) 44 (53.7) 2 (66.7) 0.737
Positive WHO symptoms screena 52 (98.1) 79 (96.3) 3 (100) 0.553
RIF resistance
Yes 1 (1.9) 3 (3.6) 0 1
Data are presented as n (%), unless otherwise stated. *Limited to among 49 patients currently receiving ART, abetween 1 and 3 values missing, b8 values missing.
Abbreviations: ART antiretroviral therapy, IQR interquartile range, LAM lipoarabinomannan, WHO World Health Organization
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to sputum-Xpert increased the diagnostic yield from
24.3% to 63.5% (n = 47/74; 2.6-fold increase; P < 0.001).
Thus, the incremental diagnostic yield of urine-LAM
was greater among patients with lower CD4 counts
(Fig. 2a, b).
Relationship between patient characteristics and
respiratory symptoms and the diagnostic yield of
Determine TB-LAM
The diagnostic yield of Determine TB-LAM was
substantially greater among patients with lower CD4
cell counts, with a maximum yield of 56.6% (95% CI
45.4-67.2) observed among those with CD4 counts of
<50 cells/μL (Fig. 3a). Yield was also much higher
among those with more severe anaemia, with the
diagnostic yield rising to 53.0% (95% CI 43.0-62.8)
among those classified as having ‘severe’ anaemia
(Fig. 3b). In contrast, the yield did not vary according to
whether patients complained of cough or sputum produc-
tion (Fig. 3c, d). Of the 53 patients with confirmed TB
who tested urine LAM-positive, 22 (41.5%) reported no
cough at the time of admission and 31 (58.5%) had no
history of sputum production during their illness. Thus, it
was notable that urine-LAM identified an important
subgroup of TB cases who had no respiratory symptoms.
Moreover, 36 of 53 urine-LAM-positive cases (67.9%)
were patients who were unable to produce a sputum
sample within the first 24 hours of admission.
Diagnostic yield among patients with pulmonary and
extrapulmonary forms of HIV-associated tuberculosis
Of the patients whose TB was diagnosed using Xpert
MTB/RIF testing of sputum obtained in the first 24 hours,
43.6% (n = 17) could be diagnosed by urine TB-LAM
instead (Table 2). Overall, 113 patients (81.3%) had EPTB
and of these 51 (45.1%) tested positive for urine-LAM,
although the yield varied substantially by the type of
EPTB. The proportion testing positive by TB-LAM was
highest among those with positive blood cultures (65.9%)
and those with positive lymph node aspirates (66.7%)
(Table 2). The yield of TB-LAM tended to be lower
among those with positive cultures of cerebrospinal fluid
(12.8%) and pleural fluid (30.8%) (Table 2).
Comparative diagnostic yield of urine-Xpert and Deter-
mine TB-LAM
The greatest yield of any diagnostic approach in this
study was the Xpert testing of urine that had been
concentrated by centrifugation. A single Xpert test on
concentrated urine yielded 59.0% of total diagnoses
(n = 82), compared with 39.1% (n = 53) for urine-LAM
(Table 2). Of the patients with positive urine Xpert
tests on a concentrated sample, 43 (52.4%) tested
positive with the Determine TB-LAM assay. Additionally,
9 of 53 patients (16.9%) testing positive on urine-
LAM had a negative urine Xpert result (using a
concentrated sample).
Fig. 2 Venn diagrams showing the proportions of (a) total tuberculosis (TB) diagnoses (n= 139) or (b) TB diagnoses in patients with CD4 cell counts <100
cells/μL (n= 74) and the proportions (diagnostic yields) which could be made using smear microscopy, sputum Xpert or urine-lipoarabinomannan (LAM)
(these tests were all conducted on samples obtained within 24 hours of admission). AFB Acid-fast bacilli
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Comparison of the characteristics and mortality risk of
tuberculosis patients with positive (n = 53) or negative
(n = 83) urine-lipoarabinomannan status
Comparing the clinical phenotype of patients with con-
firmed TB stratified according to urine-LAM status re-
vealed that those testing LAM-positive had lower CD4
cell counts and a higher prevalence and severity of an-
aemia (Table 3). In contrast, symptoms (respiratory or
otherwise) were not associated with urine-LAM status.
In multivariable analysis (Table 4), the only independent
predictors of a positive urine-LAM status among con-
firmed TB patients (n = 136) were lower CD4 cell counts
and more severe anaemia.
Having demonstrated that a positive urine-LAM status
was associated with the severity of illness, we next com-
pared survival among patients who tested urine LAM-
positive or LAM-negative (Fig. 4). Among the 136 TB
patients with urine-LAM results available, 13 of 53 test-
ing LAM-positive died (24.5%; 95% CI 13.8–38.3) com-
pared with 6 of 83 testing LAM-negative (7.2%; 95% CI
2.7–15.1; log-rank P = 0.006). Therefore, urine-LAM de-
tected TB in 13 of 19 patients (68.4%) with HIV-
associated TB who died within 90 days of study entry. In
unadjusted analyses, a greater mortality risk was also as-
sociated with male sex and rifampicin-resistant TB but
not with CD4 cell count (Table 5). In adjusted analyses,
mortality remained strongly associated with urine-LAM
status (adjusted hazards ratio 4.20; 95% CI 1.50–11.75)
and with rifampicin-resistant disease (Table 5).
Discussion
As reported in the parent study, a microbiological diag-
nosis of TB was made in one in three unselected HIV-
positive adult patients admitted to medical wards in this
South African district hospital. The prevalence is so high
in this vulnerable patient group that a simple, rapid
screening test for TB that can be immediately performed
at the time of hospital admission is highly desirable. In
the present study, we found that routine urine-LAM
testing could detect 39% of all HIV-associated TB diag-
noses and the large majority of TB diagnoses among pa-
tients dying within 90 days of admission to hospital. We
previously showed the remarkable utility of using Xpert
MTB/RIF to test urine samples concentrated by centri-
fugation, with 64% of total diagnoses being made using
samples obtained within the first 24 hours of admission
(1.6-fold more diagnoses than LAM and 2.3-fold more
than sputum Xpert testing). We are currently conduct-
ing a clinical trial in sub-Saharan Africa to assess
whether implementation of systematic testing of urine
Fig. 3 Bar charts displaying the diagnostic yields of urine-lipoarabinomannan (LAM) testing stratified according to (a) patient CD4 cell count, (b) World
Health Organization anaemia severity categorization, (c) self-reported cough and (d) self-reported sputum production. The numbers of patients in each
stratum that were urine-LAM-positive are shown beneath each chart
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samples using rapid TB assays compared to the current
sputum-based strategy results in improved survival
among HIV-patients requiring acute medical hospitliza-
tion (Rapid Urine-Based Screening for Tuberculosis to
Reduce AIDS-Related Mortality in Hospital In-Patients
in Africa [STAMP] Trial; ISRCTN71603869) [19].
Should implementation of such a screening strategy
(routine urine Xpert testing) be attempted in the countries
of southern Africa worst hit by the HIV and TB epidemics,
several potential barriers to the implementation would
exist. These include the cost to purchase and maintain the
GeneXpert platform, as well as the cost and supply chain
of Xpert MTB/RIF cartridges (especially if cartridges are
required to test both urine and sputum samples from each
patient). Our screening strategy employing urine-based
testing with Xpert MTB/RIF is also dependent upon the
availability of laboratory facilities with sufficient capacity
and biosafety equipment to undertake centrifugation of
urine samples, including an uninterrupted electricity sup-
ply. All of these requirements may potentially undermine
routine screening using Xpert testing of concentrated
urine. It was for these reasons that we sought to explore
the utility of the Determine TB-LAM lateral flow urine
assay for LAM. The potential advantages of this diagnostic
tool are self-evident: it currently costs approximately
$2.66 per test (nearly one-quarter the cost of an Xpert
Table 4 Association between characteristics of patients with tuberculosis (n = 136) and detection of lipoarabinomannan in urine
Unadjusted odds ratio
(95% CI)
Log-rank Adjusted odds ratio
(95% CI)
Log-rank
Age (for each year decrease) 1.01 (0.98–1.05) 0.491
Gender
Female 1.00 0.154
Male 1.68 (0.82–3.43)
ART status
Any ART exposure 1.00 0.748
ART naive 1.12 (0.56–2.24)
History of previous TB
Yes 1.0 0.496
No 1.29 (0.62–2.67)
CD4 category (cells/uL)
≥150 1.00 <0.001 1.00 0.002
100–149 4.55 (1.22–16.98) 4.37 (1.12–16.98)
50–99 9.53 (2.64–34.35) 6.76 (1.78–25.65)
<50 10.64 (3.61–31.36) 7.20 (2.34–22.17)
Anaemia category
None/mild 1.00 <0.001 1.00 0.051
Moderate 4.00 (1.03–15.44) 2.41 (0.57–10.24)
Severe 9.66 (2.64–35.33) 4.62 (1.14–18.74)
Self-reported sputum production
No 1.00 0.264
Yes 1.51 (0.73–3.13)
Sputum produced in the first 24 hours
Yes 1.00 0.841
No 1.08 (0.52–2.25)
Sputum sample produced during study admission
Yes 1.00 0.749
No 1.13 (0.54–2.35)
WHO screen positive
No 1.00 0.541
Yes 1.97 (0.20–19.50)
Abbreviations: ART antiretroviral therapy, CI confidence interval, TB tuberculosis, WHO World Health Organization
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MTB/RIF cartridge) and it requires no laboratory infra-
structure, no laboratory personnel or expertise, and no in-
strumentation or electricity supply.
The main perceived limitation to the use of Determine
TB-LAM is that it has only modest overall sensitivity
[13, 20]. However, sensitivity is highest among the sick-
est patients with advanced immunodeficiency and worst
prognostic characteristics, as seen in the present study
and other previous observational studies [21]. Thus, the
urine-LAM point-of-care test is ideal for use in HIV-
positive inpatients requiring acute medical admission, as
we enrolled in this study. Moreover, the limited sensitiv-
ity is greatly offset by the ease with which urine samples
can be obtained from such patients compared to spu-
tum. Whereas urine samples were readily obtained from
almost all patients within the first 24 hours, just one in
three patients could produce a sputum sample in the
same time period despite the availability of sputum in-
duction facilities. Thus, although the overall diagnostic
yield from urine-LAM was modest (39%), it greatly
exceeded the yield derived from sputum-based screening
using fluorescence microscopy or Xpert MTB/RIF, and it
doubled or more than doubled the diagnostic yield when
used in addition to sputum-based screening.
Previous studies of the diagnostic accuracy of urine-
LAM have restricted their evaluation to testing patients
selected on the basis of their ability to produce sputum
samples [8, 15, 22]. However, in the present study, just
51 (37.5%) of the 139 patients found to have a microbio-
logical diagnosis of TB reported sputum production as a
symptom during their illness, and only 37.0% could pro-
duce a sputum sample within the first 24 hours of ad-
mission. Of the true-positive urine-LAM results
obtained, 31 of 53 (58.5%) were from patients who re-
ported no sputum production (Fig. 3d). Thus, had urine-
LAM screening been restricted to those with respiratory
symptoms suggestive of pulmonary TB, almost three in
five of the TB diagnoses that could be made using urine-
LAM would have been missed. Among those with TB,
we found no association between reported symptoms
Table 5 Risk factors for mortality within 90 days of study entry among patients with confirmed tuberculosis (n = 139)
Unadjusted hazard ratio
(95% CI)
Log-rank Adjusted hazard ratio
(95% CI)
Log-rank
Age (for each year decrease) 1.01 (0.97–1.06) 0.545
Gender
Female 1.00 0.093 1.00 0.205
Male 2.17 (0.88–5.35) 1.80 (0.73–4.48)
ART status
Current ART 1.00 0.922
ART naive 1.18 (0.43–3.24)
Interrupted ART 1.29 (0.32–5.18)
CD4 category (cells/uL)
≥150 1.00 0.261
199–149 3.30 (0.74–14.75)
50–99 1.58 (0.26–9.48)
<50 2.92 (0.80–10.61)
HIV viral load (log copies/mL)
<400 1.00 0.683
≥400 1.30 (0.37–4.48)
C-reactive protein (mg/L)
<50 1.00 0.262
≥50 3.16 (0.42–23.47)
LAM-positive
No 1.00 0.007 1.00 0.004
Yes 3.56 (1.35–9.36) 4.20 (1.50–11.75)
RIF-resistant TB
No 1.00 0.082 1.00 0.032
Yes 4.90 (1.13–21.24) 8.41 (1.74–40.67)
Abbreviations: ART antiretroviral therapy; CI confidence interval, LAM lipoarabinomannan, RIF rifampicin, TB tuberculosis, WHO World Health Organization
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and a positive urine-LAM test in crude or adjusted ana-
lyses. Collectively, these findings indicate that urine-
LAM screening would be most effective when done sys-
tematically on all HIV-infected patients sick enough to
require hospital admission in high-TB-prevalence areas,
without selection according to specific symptoms. More-
over, this suggests that previous studies that have select-
ively studied patients able to produce sputum are very
likely to have under-estimated the true utility of urine-
LAM screening [23].
Many researchers have previously suggested that urine-
LAM assays lack sufficient specificity to be used as a ‘rule-
in’ diagnostic test. Indeed studies have reported specificity
to be as low as 75% [20]. In marked contrast, one of the
most important findings of this study was that assay speci-
ficity was extremely high (98.9%), indicating that this assay
has utility as a rule-in diagnostic test for TB and that the
results could be used to confidently inform the decision to
start TB treatment in this patient population. When read-
ing the lateral-flow strips, we used the agreed consensus
cut-off grade 2 band on the reference card [18]. The strips
were easy to read with 98.5% agreement between the two
independent, blinded readers. Previous studies have re-
ported variable specificity (75–99%) [20] and this may not
only relate to differences in interpretation of the test-strip
bands, but also to the rigour of the microbiological refer-
ence standard [13]. We designed this study to optimize as-
sessment of LAM specificity, with an average of 5.6
reference standard tests being done for each patient.
Moreover, the clinical samples were obtained from a me-
dian of three different anatomic compartments. This very
comprehensive microbiological reference standard likely
underlies the high specificity we observed.
The diagnostic yield varied substantially with CD4 cell
count, with no useful yield among those with counts >200
cells/μL, but with a gradually increasing yield within lower
CD4 cell count strata, reaching a maximum of 56.6%
among those with counts of 0–49 cells/μL. The yield from
urine-LAM screening was independent of ART status. This
study confirms that assay utility is restricted to HIV-
infected patients with CD4 cell counts of <200 cells/μL as
previously shown among HIV-infected medical inpatients
[8, 22] and HIV-infected outpatients starting ART [15]. We
also found a strong relationship between higher diagnostic
yield and increasing severity of anaemia with a very poor
overall yield among those with no or mild anaemia, as we
have previously reported among outpatients [24]. Thus, pa-
tients with moderate or severe HIV-associated anaemia
may especially benefit from TB screening using urine-
LAM. In settings that do not permit universal TB screening
due to limited resources, moderate or severe anaemia (in
addition to advanced immunodeficiency) may serve as a
simple marker for entry into the TB diagnostic algorithm.
During prospective follow-up, mortality was also found
to be substantially greater among those testing urine-LAM
positive in both crude and adjusted analyses. Other studies
too have found a strong association between positive LAM
status and mortality, including a recent meta-analysis that
found a more than two-fold increased odds of mortality as-
sociated with LAM-positivity [21, 25–29]. Recently, a
multi-country randomized controlled trial based in sub-
Saharan Africa found that urine-LAM testing in addition to
standard-of-care TB diagnostics was associated with a 17%
(95% CI 4–28) relative risk reduction in 8-week all-cause
mortality among HIV-infected patients requiring acute
medical admission; in those with CD4 counts <50 cells/μL,
Fig. 4 Cumulative probability of death within 90 days of study enrolment of patients with confirmed HIV-associated tuberculosis (n = 136 with urine
samples available), stratified according to urine-lipoarabinomannan (LAM) status. For ease of viewing, a magnified view is shown in the upper right
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the implementation of LAM was associated with a 29%
(95% CI 10–44) relative risk reduction in 8-week all-cause
mortality [30]. This was the first randomized controlled
trial to demonstrate a mortality reduction associated with
the implementation of a TB detection assay [31].
The Determine TB-LAM assay underwent expert review
by the WHO in 2015. On the basis of a Cochrane review
of all available data (that included unpublished data from
the present study) [20] as well as the randomized trial by
Peter et al. demonstrating a mortality benefit associated
with LAM [30], the WHO now conditionally recommends
that urine-LAM testing be used for all HIV-positive pa-
tients with CD4 counts <100 cells/μL who require
hospitalization and have signs and symptoms of TB, as
well as for HIV-positive inpatients who are seriously ill, ir-
respective of their CD4 cell count. While the sensitivity of
the assay is generally modest, various factors favour imple-
mentation of this assay as a rule-in test for TB among
HIV-positive inpatients by national TB programmes in
resource-limited settings [32]. These include a proven
mortality benefit, extremely high specificity and positive
predictive value when a grade 2 cut-off is used, low-cost
(consumable cost of $2.66 per test strip), and that it can
be done at the point of care without laboratory expertise
or instrumentation [22, 33].
Strengths of this study include the recruitment of con-
secutive admissions without selection according to pre-
senting symptoms or other criteria. Patients were very
thoroughly investigated, yielding a large number of TB
diagnoses and providing a comprehensive reference stand-
ard to assess the diagnostic accuracy of urine-LAM. We
believe that this has provided the most rigorous assess-
ment of the diagnostic accuracy of Determine TB-LAM to
date. Patients were well characterized and are likely to be
representative of HIV-infected medical admissions in
countries with a high TB burden. The consistency in find-
ings of post-mortem studies reporting on the burden of
undiagnosed disseminated TB in HIV-infected inpatient
deaths across the African continent [6] suggests that these
findings may be of relevance throughout Africa. Outcome
data at 90 days (~95% available) allowed the prognostic
value of urine-LAM to be carefully assessed. Weaknesses
include the fact that sputum could only be obtained from
57.4% of participants during their admission despite access
to sputum induction facilities. This may have resulted in
under-ascertainment of pulmonary TB cases. However,
the large numbers of extrapulmonary specimens obtained
(Additional file 1: Table S1) likely minimized the under-
diagnosis of TB. The low proportion of patients who could
provide a sputum sample despite the availability of spu-
tum induction facilities was an important reason for the
relatively poor yield of sputum diagnostics in this study.
This in part reflects the design of the study, which in-
volved screening all HIV-infected patients whether they
reported a cough or not (approximately 80% of those who
self-reported a cough were able to produce a sputum sam-
ple). Had the proportion producing sputum been higher
(e.g. through enhanced sputum induction procedures and
transporting sicker patients to the induction facility with
medical support), then the proportion of participants diag-
nosed using urine-LAM alone (rather than sputum Xpert
or smear microscopy) may have been lower. However,
sputum induction facilities and resources for additional
medical support in hospital services are for the most part
not available in sub-Saharan Africa. Another weakness is
that the study was done at a single site and urine-LAM
testing was done retrospectively on frozen samples. How-
ever, the feasibility of prospectively testing urine samples
at the point of care has been demonstrated in other stud-
ies [22, 30]. Our results cannot be generalized to the test-
ing of HIV-infected children, in whom the assay has
unfortunately not been found to have utility [34]. Ongoing
research on pathogen and host diagnostic urine bio-
markers for TB may yield urine assays with improved per-
formance characteristics in the future [35–37].
Conclusions
We have rigorously evaluated the Determine TB-LAM
diagnostic urine assay and demonstrated that its speci-
ficity is extremely high and it provides substantial in-
cremental diagnostic yield when used as a routine
screening test on unselected HIV-infected adults newly
admitted to hospital. The addition of urine-LAM
screening doubled the diagnostic yield derived from
systematic screening of sputum using Xpert MTB/RIF.
Much of the benefit from urine-LAM testing was
among TB patients without respiratory symptoms or
sputum production. In conjunction with recently pub-
lished WHO recommendations, this study further sup-
ports the implementation of the Determine TB-LAM
lateral-flow assay as an initial, routine point-of-care
rule-in test for TB among HIV-patients requiring
hospitalization in settings with a high TB burden.
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